TRANSFORMER: Bipolar androgen therapy (BAT) versus enzalutamide (E) for castration-resistant metastatic prostate cancer (mCRPC).
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.5517
Abstract: 5517Background: Rapid cycling between high and low testosterone (T) (i.e BAT) produces tumor response in mCRPC, and may overcome resistance to newer AR therapies. Here we report a randomized study ... read more here.
Keywords: mcrpc; bat; therapy bat; androgen therapy ... See more keywords
Experience of bipolar androgen therapy (BAT) in Argentinian oncology centres
Sign Up to like & getrecommendations! Published in 2022 at "ecancermedicalscience"
DOI: 10.3332/ecancer.2022.1480
Abstract: Background Previous studies with bipolar androgen therapy (BAT) have shown clinical activity in metastatic Castration Resistant Prostate Cancer (mCRPC) as well as the potential to re-sensitise prostate cancer cells to prior androgen receptor-targeted agents. None… read more here.
Keywords: oncology; androgen therapy; bat; treatment ... See more keywords